Form 144 Filer Information

FORM 144

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144. Filer illiorillation		
Filer CIK	0001784487	
Filer CCC	XXXXXXXX	
Is this a LIVE or TEST Filing?	● LIVE ○ TEST	
Submission Contact Information		
Name		
Phone		
E-Mail Address		
144: Issuer Information		
Name of Issuer	Adaptimmune Therapeutics PLC	
SEC File Number	001-37368	
Address of Issuer	60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE UNITED KINGDOM OX14 4RX	
Phone	44 1235 430000	
Name of Person for Whose Account the Securities are To Be Sold	Lunger John	
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filling this notice.		
Relationship to Issuer	Chief Patient Supply Officer	
144: Securities Information		
Title of the Class of Securities To Be Sold	American Depositary Shares	
Name and Address of the Broker	Maxim Group 300 Park Ave 16th Floor NEW YORK NY 10022	
Number of Shares or Other Units To Be Sold	9739	
Aggregate Market Value	5726.00	
Number of Shares or Other Units Outstanding	255880000	
Approximate Date of Sale	01/13/2025	
Name the Securities Exchange	NASDAQ	

144: Securities Information

Title of the Class of Securities To Be Sold	American Depositary Shares
Name and Address of the Broker	MAXIM GROUP 300 Park Ave 16th Floor NEW YORK NY 10022
Number of Shares or Other Units To Be Sold	9803
Aggregate Market Value	5635.00
Number of Shares or Other Units Outstanding	255880000
Approximate Date of Sale	01/15/2025
Name the Securities Exchange	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	American Depositary Shares
Date you Acquired	01/13/2025
Nature of Acquisition Transaction	Sell to cover exercise (cashless)
Name of Person from Whom Acquired	Adaptimmune Therapeutics plc
Is this a Gift?	Date Donor Acquired
Amount of Consuition Apprised	0720
Amount of Securities Acquired	9739
Date of Payment	01/13/2025
Nature of Payment	COMPENSATION

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

144: Securities To Be Sold

Title of the Class	American Depositary Shares
Date you Acquired	01/15/2025
Nature of Acquisition Transaction	Sell to cover exercise (cashless)
Name of Person from Whom Acquired	Adaptimmune Therapeutics plc
Is this a Gift?	□ Date Donor Acquired
Amount of Securities Acquired	9803
Date of Payment	01/15/2025
Nature of Payment	COMPENSATION

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Lunger John

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)